[go: up one dir, main page]

ATE156361T1 - Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
ATE156361T1
ATE156361T1 AT93920157T AT93920157T ATE156361T1 AT E156361 T1 ATE156361 T1 AT E156361T1 AT 93920157 T AT93920157 T AT 93920157T AT 93920157 T AT93920157 T AT 93920157T AT E156361 T1 ATE156361 T1 AT E156361T1
Authority
AT
Austria
Prior art keywords
protein
delayed release
medicinal products
contained medicinal
sustained
Prior art date
Application number
AT93920157T
Other languages
English (en)
Inventor
Michael J Hageman
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE156361T1 publication Critical patent/ATE156361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT93920157T 1992-09-21 1993-08-23 Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe ATE156361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94787292A 1992-09-21 1992-09-21
US96336592A 1992-10-20 1992-10-20

Publications (1)

Publication Number Publication Date
ATE156361T1 true ATE156361T1 (de) 1997-08-15

Family

ID=27130263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920157T ATE156361T1 (de) 1992-09-21 1993-08-23 Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe

Country Status (12)

Country Link
US (1) US6011011A (de)
EP (1) EP0661989B1 (de)
JP (2) JP3756512B2 (de)
AT (1) ATE156361T1 (de)
AU (1) AU5018693A (de)
DE (1) DE69312947T2 (de)
DK (1) DK0661989T3 (de)
ES (1) ES2107051T3 (de)
GR (1) GR3024632T3 (de)
MX (1) MX9305729A (de)
TW (1) TW224055B (de)
WO (1) WO1994006452A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130222C (zh) 1996-01-11 2003-12-10 法玛西雅厄普约翰美国公司 水性延长释放配剂
KR100594519B1 (ko) * 1996-07-03 2007-03-02 앨자 코포레이션 비수성양성자성펩티드제제
KR100593221B1 (ko) * 1996-07-03 2007-03-02 알자 코포레이션 비수성극성비양성자성펩타이드제제
EP0909175B1 (de) * 1996-07-03 2003-06-04 Alza Corporation Nicht-waessrige protische peptidzubereitungen
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (de) 1996-10-16 2000-09-09 Alza Corp
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
AU2002211629A1 (en) * 2000-10-10 2002-04-22 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
KR100838219B1 (ko) * 2001-07-13 2008-06-13 동아제약주식회사 인간성장호르몬의 지속적인 방출이 가능한 생분해성약학적 조성물 및 미립구 제형
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
LT2891666T (lt) 2002-10-16 2017-10-10 Purdue Pharma L.P. Antikūnai, kurie prisiriša su ląstelėmis susijusį ca 125/o722p ir jų naudojimo būdas
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1663296A4 (de) * 2003-09-25 2009-11-25 Cangene Corp Flüssige menschliche wachstumshormonformulierung mit polyethylenglykol
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
CA2595457A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
EP1928551B1 (de) * 2005-06-10 2012-05-30 Althea Technologies, Inc. Verfahren zur reduzierung der oxalat-konzentration durch verabreichung von oxalat-oxidase-kristallen
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5808037B2 (ja) 2007-10-19 2015-11-10 サーコード バイオサイエンス インク． 糖尿病性網膜症の治療のための組成物及び方法
BRPI0819235A2 (pt) * 2007-11-02 2017-08-22 Acrux Dds Pty Ltd Sistema de distribuição transdérmica para hormônios e esteróides
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
DE102009056745A1 (de) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung von Peptiden
JP2013515081A (ja) * 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
BR112012015461A2 (pt) * 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2985784T3 (es) 2011-11-18 2024-11-07 Regeneron Pharma Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
AR091784A1 (es) * 2012-07-17 2015-02-25 Bayer New Zealand Ltd Formaciones inyectables de antibiotico y sus metodos de aplicacion
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
MY193964A (en) * 2015-10-16 2022-11-03 Regeneron Pharma Stable protein compositions
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1185340A (en) * 1967-12-19 1970-03-25 Gen Foods Corp Water Dispersable Hydrophilic Colloid Composition.
US4041155A (en) * 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
FR2606597B1 (fr) * 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5004728A (en) * 1988-03-11 1991-04-02 The Trustees Of The University Of Pennsylvania Methods of increasing milk yields in ruminants
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
ZA903756B (en) * 1989-05-16 1991-02-27 Puetter Medice Chem Pharm Pharmaceutical preparation
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments

Also Published As

Publication number Publication date
TW224055B (de) 1994-05-21
WO1994006452A1 (en) 1994-03-31
ES2107051T3 (es) 1997-11-16
DK0661989T3 (da) 1998-03-02
DE69312947T2 (de) 1998-01-08
AU5018693A (en) 1994-04-12
GR3024632T3 (en) 1997-12-31
US6011011A (en) 2000-01-04
JP2004285079A (ja) 2004-10-14
JPH08501305A (ja) 1996-02-13
EP0661989A1 (de) 1995-07-12
DE69312947D1 (de) 1997-09-11
MX9305729A (es) 1994-03-31
EP0661989B1 (de) 1997-08-06
JP3756512B2 (ja) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE156361T1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
AU6819294A (en) Oral drug delivery compositions and methods
EP0570916A3 (de) Menschliches rekombinantes Serum-Albumin, Verfahren zur dessen Herstellung und diese enthaltende pharmazeutischen Präparate.
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
EP1686172A3 (de) Herztransplantate und dafür nützliche Zellzusammensetzungen
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP0422125A4 (en) Platelet blocking peptides
EA200000685A1 (ru) Комплекс ifnar2/ifn
WO2002058589A3 (en) Agents and methods for promoting bone growth
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
AU3629389A (en) Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same
EP1174439A3 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
CA2163805A1 (en) Novel activating factor of leukocytes
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee